Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Adam L Boxer, Anthony E Lang, Murray Grossman, David Knopman, Bruce L Miller, Lon S Schneider, Rachelle S Doody, Andrew J Lees, Lawrence I Golbe, David Williams, Jean-Christophe Corvol, Albert Ludolph, David J Burn, Stefan Lorenzl, Irene Litvan, Erik D Roberson, Gunter U Hoglinger, Mary Koestler, Clifford R Jack Jr, Viviana Van DeerlinChristopher Randolph, Iryna V Lobach, Hilary W Heuer, Illana Gozes, Lesley Parker, Steve Whitaker, Joe Hirman, Alistair J Stewart, Michael S Gold, Bruce H Morimoto

Research output: Contribution to journalArticleResearchpeer-review

196 Citations (Scopus)


Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and effi cacy of davunetide in patients with PSP. Methods In a double-blind, parallel group, phase 2/3 trial, participants were randomly assigned with permuted blocks in a 1:1 ratio to davunetide (30 mg twice daily, intranasally) or placebo for 52 weeks at 48 centres in Australia, Canada, France, Germany, the UK, and the USA. Participants met the modifi ed Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP. Primary endpoints were the change from baseline in PSP Rating Scale (PSPRS) and Schwab and England Activities of Daily Living (SEADL) scale at up to 52 weeks. All participants and study personnel were masked to treatment assignment. Analysis was by intention to treat. The trial is registered with Clinicaltrials.gov, number NCT01110720. Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77 ) completed the study (118 and 156 in the davunetide and placebo groups, respectively). There were no diff erences in the davunetide and placebo groups in the baseline PSPRS and SEADL. The davunetide and placebo groups did not diff er in the change from baseline in PSPRS (median 11?8 [95 CI 10?5 to 13?0] vs 11?8 [10?5 to 13?0], respectively, p=0?41) or SEADL (?0?20 [?0?20 to ?0?17] vs ?0?20 [?0?22 to ?0?17], respectively, p=0?92). 54 serious adverse events were reported in each of the treatment groups, including 11 deaths in the davunetide group and ten in the placebo group. The frequency of nasal adverse events was greater in the davunetide group than in the placebo group (epistaxis 18 [12 of 156 vs 13 [8 of 156, rhinorrhoea 15 [10 vs eight [5 , and nasal discomfort 15 [10 vs one [
Original languageEnglish
Pages (from-to)676 - 685
Number of pages10
JournalThe Lancet Neurology
Issue number7
Publication statusPublished - 2014

Cite this